Share this article
Share this article
HALIFAX, NS, Jan. 11, 2021 /PRNewswire/ - Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the U.S. launch of its new CRYO
check Hex LA kit. Expansion to the U.S. follows successful launches in Canada, the European Union, Australia, and New Zealand.
CRYOcheck Hex LA: Intended for use in clinical labs to aid in the detection of lupus anticoagulant (LA) in human plasma, Hex LA is the first commercially available hexagonal phase LA test available in a frozen format, allowing for fast and easy preparation. Designed to work on many common automated coagulation analyzers, Hex LA offers valuable time savings to today’s busy labs. (CNW Group/Precision BioLogic)
Share this article
Share this article
ATLANTA, Jan. 11, 2021 /PRNewswire/ LifeBrite, an acclaimed national hospital, laboratory, and research and development company, strives to increase COVID-19 testing in Georgia, Florida, North Carolina, South Carolina, Mississippi, and Alabama as the pandemic continues. Its affiliates LifeBrite Hospital Group and Better to Know work together to provide on-site and mobile testing. Test collection is available at hospitals, healthcare provider offices, and places of employment.
Christian Fletcher, CEO of LifeBrite, continues dedicating his career to improving community health in urban and rural areas. He sees expanding COVID-19 testing as an opportunity for LifeBrite to rise to the moment and further fulfill its mission to ensure that quality care and ancillary health service offerings are available to all regardless of geographical location.
Voiceitt Named as CES 2021 Innovation Awards Honoree
USA - English
News provided by
Share this article
Share this article
TEL AVIV, Israel, Jan. 11, 2021 /PRNewswire/ Voiceitt, a leader in commercial speech recognition for atypical speech, today announced that it has been named a CES® 2021 Innovation Awards Honoree. The company was recognized in the
Accessibility category for its first-of-its-kind app that provides a simple, accessible way for people with speech and motor impairments to communicate using their own voice. The announcement was made ahead of the first-ever, all-digital CES 2021, the world s most influential technology event, happening Jan. 11-14, 2021.
Every year, the CES Innovation Awards program, owned and produced by the Consumer Technology Association (CTA)®, honors outstanding design and engineering in consumer technology products across 28 product categories. An elite panel of industry expert judges, including members of the media, designers, enginee
Share this article
Share this article
SAN RAFAEL, Calif., Jan. 10, 2021 /PRNewswire/ BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A. This is the largest global Phase 3 study to date for any gene therapy in any indication, with 134 participants. All participants in the study received a single dose of valoctocogene roxaparvovec and completed a year or more of follow-up.
Figure 1: Box-and-Whiskers Plot of Factor VIII Activity in 4-Week Intervals, Subset Population (N=17 ) - Key: The boxes show the interquartile ranges with the lines in the boxes indicating medians. The ends of the whiskers represent the minimum and maximum values and diamonds indicate the means. - Includes only HIV-negative subjects dosed 2 or more years prior to Nov 2020 data cut date. One subject was lost t
/PRNewswire/ BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces it has restructured a clinical development agreement.